 OSLO, Norway--BUSINESS WIRE--- ULTI ClinicalTrials--Ultimovacs ASA Ultimovacs OSE ULTI, a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in Frontiers in Immunology of its positive long-term Overall Survival OS data from the Phase I trial evaluating the Companys universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma. As published in the journal, in addition to the achievement of the p 